Across the country, states are shelling out incentives ranging from free beer to $1 million lotteries to encourage residents to get their Covid-19 shots. But is the effort to boost vaccination rates working? And is it worth the cost? Photo composite: Adam Falk/The Wall Street Journal
Vaccines are medicines that train the body to defend itself against future disease, and they have been saving human lives for hundreds of years. Vaccines are medicines that train the body to defend itself against future disease.
The rollout of the Johnson & Johnson vaccine has been paused in the US, Europe and South Africa after reports of rare blood clotting in a very small number of people. Health authorities said they were halting the use of the shot while they investigate the cases — and that they were doing this out of “an abundance of caution.” The Astra Zeneca jab was also recently temporarily suspended in some countries after being linked to rare blood clots. Authorities are calling it a short “pause.” The US’s Johnson and Johnson vaccine has hit the same stumbling block as the UK’s AstraZeneca jab did last month: a likely link to a rare and deadly blood clot. Use of Johnson and Johnson’s Janssen vaccine has now been halted across the US, Europe and South Africa, with health authorities investigating six incidents of clotting in younger women, one of them fatal. The US-developed vaccine uses an adenovirus to trigger immunity – the same mechanism as the UK’s AstraZeneca vaccine. It accounts for roughly 5 percent of vaccines delivered so far in the US. This is a setback to Europe, too. Johnson and Johnson announced it will delay it’s rollout on the continent. The company had already started processing an order from the EU of 200 million doses. The Janssen jab has been partially rolled out in Africa, where a majority of countries don’t have enough vaccines even for their healthcare workers. The African Union signed a deal for 220 million doses this year. But US authorities remain hopeful. They’re saying it could only be a matter of days before the rollout resumes.
Mayo Clinic Insights: Dr. Swift discusses what you need to know about the new Johnson & Johnson COVID-19 vaccine. For more up to date information about COVID-19, visit https://mayocl.in/3aUioXa
Technologies in development for delivering vaccines include Enesi’s dissolving implants, microneedle patches, electrical-pulse systems, nasal sprays and even pills.
Some firms are developing their own vaccines against Covid-19, while others are aiming to reformulate some of the dozens already in development or being rolled out world-wide. Some are sitting this pandemic out in the hope of being ready for the next one.
All are in the early to mid-stages of development and clinical testing, suggesting it might be months if not years before they come to market. Big pharmaceutical companies have so far shown limited interest.
There are all sorts of different vaccines but many of them share specific types of ingredients. Josh Toussaint-Strauss talks to Professor Adam Finn to find out what is in most conventional vaccines, as well as what they do to our bodies when we take them – and why the mRNA Covid jabs from Pfizer/BioNTech, Oxford/AstraZeneca and Moderna work differently.
Vaccine science and technology is advancing. Next generation vaccines could change how we combat infectious diseases, and it’s important to understand how the technology works.
Researchers are scrambling to understand the biology of new coronavirus variants and the impact they might have on vaccine efficacy.
Around the world, concern is growing about the impact that new, faster-spreading variants of the SARS-CoV-2 virus will have on the pandemic.
In this episode of Coronapod, we discuss what these variants are, and the best way to respond to them, in the face of increasing evidence that some can evade the immunity produced by vaccination or previous infection.